Search

Your search keyword '"Sohn, Joo Hyuk"' showing total 272 results
Start Over Author "Sohn, Joo Hyuk"
272 results on '"Sohn, Joo Hyuk"'

1. Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study

Author

Yamashita, Toshinari, Sohn, Joo Hyuk, Tokunaga, Eriko, Niikura, Naoki, Park, Yeon Hee, Lee, Keun Seok, Chae, Yee Soo, Xu, Binghe, Wang, Xiaojia, Im, Seock-Ah, Li, Wei, Lu, Yen-Shen, Aguilar, Cecilia Orbegoso, Nishijima, Soichiro, Nishiyama, Yuji, Sugihara, Masahiro, Modi, Shanu, and Tsurutani, Junji

Published
2024
Full Text
View/download PDF

2. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

Author

Balmaña, Judith, Fasching, Peter A., Couch, Fergus J., Delaloge, Suzette, Labidi-Galy, Intidhar, O’Shaughnessy, Joyce, Park, Yeon Hee, Eisen, Andrea F., You, Benoit, Bourgeois, Hughes, Gonçalves, Anthony, Kemp, Zoe, Swampillai, Angela, Jankowski, Tomasz, Sohn, Joo Hyuk, Poddubskaya, Elena, Mukhametshina, Guzel, Aksoy, Sercan, Timcheva, Constanta V., Park-Simon, Tjoung-Won, Antón-Torres, Antonio, John, Ellie, Baria, Katherine, Gibson, Isabel, and Gelmon, Karen A.

Published
2024
Full Text
View/download PDF

3. Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA

Author

Bae, Mingyun, Kim, Gyuhee, Lee, Tae-Rim, Ahn, Jin Mo, Park, Hyunwook, Park, Sook Ryun, Song, Ki Byung, Jun, Eunsung, Oh, Dongryul, Lee, Jeong-Won, Park, Young Sik, Song, Ki-Won, Byeon, Jeong-Sik, Kim, Bo Hyun, Sohn, Joo Hyuk, Kim, Min Hwan, Kim, Gun Min, Chie, Eui Kyu, Kang, Hyun-Cheol, Kong, Sun-Young, Woo, Sang Myung, Lee, Jeong Eon, Ryu, Jai Min, Lee, Junnam, Kim, Dasom, Ki, Chang-Seok, Cho, Eun-Hae, and Choi, Jung Kyoon

Published
2023
Full Text
View/download PDF

4. In Reply

Author

Rugo, Hope S, Huober, Jens, Garcia-Saenz, Jose A, Masuda, Norikazu, Sohn, Joo Hyuk, Andre, Valerie AM, Barriga, Susana, Cox, Joanne, and Goetz, Matthew

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Good Health and Well Being, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

This letter to the editor responds to Badoui et al. regarding data on abemaciclib dosages and adverse events.

Published
2021

5. Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3

Author

Rugo, Hope S, Huober, Jens, García‐Sáenz, José A, Masuda, Norikazu, Sohn, Joo Hyuk, Andre, Valerie AM, Barriga, Susana, Cox, Joanne, and Goetz, Matthew

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Cancer, Breast Cancer, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Breast Neoplasms, Female, Fulvestrant, Humans, Receptor, ErbB-2, Abemaciclib, Safety, Advanced breast cancer, Diarrhea, Neutropenia, Receptor, erbB-2, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundAbemaciclib demonstrated efficacy in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Here we provide a comprehensive summary of the most common adverse events (AEs), their management, and whether AEs or dose reductions influenced progression-free survival (PFS), in the MONARCH 2 and 3 trials.Materials and methodsIncidence of the most clinically relevant AEs, management, and outcomes were summarized. Time-dependent covariate analyses examined the impact of dose reductions on PFS. PFS was estimated for patients with and without early onset of diarrhea or neutropenia.ResultsThe most frequently reported AE was diarrhea, with clinically significant diarrhea (grade ≥2) reported for 42.8% of patients taking abemaciclib. Median time to onset was 1 week, and duration ranged from 6 to 12 days, depending on grade and study. Diarrhea was adequately managed by antidiarrheal medication (72.8%), dose omissions (17.3%), and reductions (16.7%). The highest rates of grade ≥2 diarrhea were observed in the first cycles and decreased in subsequent cycles. Neutropenia (grade ≥3) occurred in 25.4% of abemaciclib-treated patients. Neutropenia resolved with dose omissions (16.8%) and/or dose reductions (11.2%). Incidence of febrile neutropenia (0.7%) or other relevant grade ≥3 hematological events (

Published
2021

7. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Author

Kim, Sung-Bae, Dent, Rebecca, Im, Seock-Ah, Espié, Marc, Blau, Sibel, Tan, Antoinette R, Isakoff, Steven J, Oliveira, Mafalda, Saura, Cristina, Wongchenko, Matthew J, Kapp, Amy V, Chan, Wai Y, Singel, Stina M, Maslyar, Daniel J, Baselga, José, investigators, LOTUS, Lee, Keun Seok, Wang, Hwei-Chung, Tan, Antoinette, Sohn, Joo Hyuk, De Laurentiis, Michelino, Estevez, Laura Garcia, Huang, Chiun-Sheng, Romieu, Gilles, Velez, Michel, Villanueva, Rafael, Conte, Pier Franco, Dakhil, Shaker, Debled, Marc, Martin, Antonio Gonzalez, Hurvitz, Sara, Kim, Jee Hyun, Levy, Christelle, Rovira, Pedro Sanchez, Seo, Jae Hong, Valero, Vicente, Vidal, Gregory, Wong, Andrea, Allison, Mary Ann K, Figlin, Robert, Chan, David, Chen, Shin-Cheh, Chen, Yen-Hsun, Cobleigh, Melody, De Braud, Filippo, Dirix, Luc, Hansen, Vincent, Bessard, Anne Hardy, Iannotti, Nicholas, Isakoff, Steven, Lawler, William, Montaño, Alvaro, Salkini, Mohamad, and Seigel, Leonard

Subjects
Clinical Research, Breast Cancer, Clinical Trials and Supportive Activities, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Administration, Oral, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Confidence Intervals, Disease-Free Survival, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Maximum Tolerated Dose, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Paclitaxel, Patient Selection, Placebos, Prognosis, Proportional Hazards Models, Proto-Oncogene Proteins c-akt, Risk Assessment, Survival Analysis, Treatment Outcome, Triple Negative Breast Neoplasms, LOTUS investigators, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundThe oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast cancer. The LOTUS trial investigated the addition of ipatasertib to paclitaxel as first-line therapy for triple-negative breast cancer.MethodsIn this randomised, placebo-controlled, double-blind, phase 2 trial, women aged 18 years or older with measurable, inoperable, locally advanced or metastatic triple-negative breast cancer previously untreated with systemic therapy were recruited from 44 hospitals in South Korea, the USA, France, Spain, Taiwan, Singapore, Italy, and Belgium. Enrolled patients were randomly assigned (1:1) to receive intravenous paclitaxel 80 mg/m2 (days 1, 8, 15) with either ipatasertib 400 mg or placebo once per day (days 1-21) every 28 days until disease progression or unacceptable toxicity. Randomisation was by stratified permuted blocks (block size of four) using an interactive web-response system with three stratification criteria: previous (neo)adjuvant therapy, chemotherapy-free interval, and tumour PTEN status. The co-primary endpoints were progression-free survival in the intention-to-treat population and progression-free survival in the PTEN-low (by immunohistochemistry) population. This ongoing trial is registered with ClinicalTrials.gov (NCT02162719).FindingsBetween Sept 2, 2014, and Feb 4, 2016, 166 patients were assessed for eligibility and 124 patients were enrolled and randomly assigned to paclitaxel plus ipatasertib (n=62) or paclitaxel plus placebo (n=62). Median follow-up was 10·4 months (IQR 6·5-14·1) in the ipatasertib group and 10·2 months (6·0-13·6) in the placebo group. Median progression-free survival in the intention-to-treat population was 6·2 months (95% CI 3·8-9·0) with ipatasertib versus 4·9 months (3·6-5·4) with placebo (stratified hazard ratio [HR] 0·60, 95% CI 0·37-0·98; p=0·037) and in the 48 patients with PTEN-low tumours, median progression-free survival was 6·2 months (95% CI 3·6-9·1) with ipatasertib versus 3·7 months (1·9-7·3) with placebo (stratified HR 0·59, 95% CI 0·26-1·32, p=0·18). The most common grade 3 or worse adverse events were diarrhoea (14 [23%] of 61 ipatasertib-treated patients vs none of 62 placebo-treated patients), neutrophil count decreased (five [8%] vs four [6%]), and neutropenia (six [10%] vs one [2%]). No colitis, grade 4 diarrhoea, or treatment-related deaths were reported with ipatasertib. One treatment-related death occurred in the placebo group. Serious adverse events were reported in 17 (28%) of 61 patients in the ipatasertib group and nine (15%) of 62 patients in the placebo group.InterpretationProgression-free survival was longer in patients who received ipatasertib than in those who received placebo. To our knowledge, these are the first results supporting AKT-targeted therapy for triple-negative breast cancer. Ipatasertib warrants further investigation for the treatment of triple-negative breast cancer.FundingF Hoffmann-La Roche.

Published
2017

8. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Author

Agajanian, Richy, Ahmad, Rizvana, Aktas, Bahriye, Alencar, Victor Hugo, Amadori, Dino, Andrade, Jurandyr, André Franke, Fábio, Angiolini, Catia, Aogi, Kenjiro, Armor, Jess, Arpornwirat, Wichit, Assersohn, Laura, Audeh, William, Aulitzky, Walter, Azevedo, Sergio, Bartoli, Maria Alejandra, Batista Lopez, Norberto, Bianconi, María, Biganzoli, Laura, Birhiray, Ruemu, Bitina, Marianna, Blachy, Ron, Blackwell, Kimberly, Blanchard, Rita, Blanchet, Paulette, Boiangiu, Ion, Bower, Barbara, Brezden-Masley, Christine, Brufsky, Adam, Budde, Leanne, Caguioa, Priscilla, Calvo, Lourdes, Campone, Mario, Carroll, Robert R., Castro, Hugo, Chan, Valorie, Charu, Veena, Cinieri, Saverio, Clemens, Michael, Conejo, Emilio Alba, Côrtes, Eduardo, Coudert, Bruno, Cronemberger, Eduardo, Cubero, Daniel, Dakhil, Shaker, Daniel, Brooke, Davidson, Neville, De Fatima Gaui, Maria, De La Cruz, Susana, Del Pilar, Maria, Delgado, Gilson, Ellerton, John A., Estuardo, Cesar, Fehrenbacher, Louis, Ferrero, Jean-Marc, Flynn, Patrick J., Foszczynska-Kloda, Malgorzata, Franco, Sandra, Fujii, Hirofumi, Gallagher, Chris, Gamucci, Teresa, Giacomi, Nora, Gil I Gil, Miguel, Gonzalez Martin, Antonio, Gorbunova, Vera, Gotovkin, Eugeny, Green, Nathan, Grincuka, Elza, Grischke, Eva-Maria, Hansen, Vincent, Hargis, Jeffrey, Hauschild, Maik, Hegg, Roberto, Hendricks, Carolyn, Hermann, Robert, Hoff, Paulo, Horiguchi, Jun, Hornedo Muguiro, Javier, Iacobelli, Stefano, Inoue, Kenichi, Ismael, Gustavo, Itoh, Yoshinori, Iwata, Dr Hiroji, Jendiroba, Davi, Jochim, Rosa, Jones, Alison, Just, Marianne, Kallab, Andre, Karwal, Mark, Kashiwaba, Masahiro, Kato, Giraldo, Kaufman, Peter A., Kellokumpu-Lehtinen, Pirkko, Kirsch, Andreas, Kiselev, Igor, Klein, Paula, Kohno, Norio, Kopp, Mikhail, Kostovska-Maneva, Liljana, Kotliar, Mauricio, Kudaba, Iveta, Kümmel, Sherko, Kuroi, Katsumasa, Lacava, Juan, Latini, Luciano, Lee, Soo Chin, Lichinitser, Mikhail, Lobo, Christopher, Maintz, Christoph, Maneecahvakajorn, Jedzada, Marmé, Alexander, Martinez, Gloria, Masuda, Norikazu, Matwiejuk, Mario, Merculov, Vladimir, Michaelson, Richard, Miguel, Luis, Monroy, Hernandez, Montemurro, Filippo, Morales, Serafin, Moura, Rodrigo, Mueller, Volkmar, Mulatero, Clive, Nakagami, Kazuhiko, Nakayama, Takahiro, Neidhart, Jeff, Nguyen, An, Nishimura, Reiki, Ogata, Haruki, O'reilly, Susan, O'rourke, Timothy, Otero Reye, Douglas, Ouyang, Xuenong, Patel, Ravi, Patel, Taral, Pedrini, Jose Luiz, Pereira, Rodrigo, Perez, Alejandra, Peterson, Carol, Pienkowski, Tadeusz, Pinczowski, Helio, Polikoff, Jonathan, Polkowski, Wojciech, Price, Paola Edith, Prill, Sue, Priou, Frank, Purkalne, Gunta, Pyrhoenen, Seppo, Quackenbush, Robert, Rai, Yoshiaki, Ribelles, Nuria, Ro, Jungsil, Robinson, Anne, Robles, Robert, Rodriguez, Gladys, Roman, Laslo, Saji, Shigehira, Sanchez-Rovira, Pedro, Sato, Nobuaki, Schmidt, Marcus, Schumacher, Claudia, Senecal, Frank, Sharma, Priyanka, Shen, Zhenzhou, Shirinkin, Vadim, Simoncini, Edda, Sirisinha, Thitiya, Smith, Raymond, Sohn, Joo-Hyuk, Soldic, Zeljko, Soria, Tania, Spicer, Darcy, Srimuninnimit, Vichien, Sriuranpong, Virote, Staroslawska, Elzbieta, Stefanovski, Petar, Sunpaweravong, Patrapim, Taguchi, Julie, Takeda, Koji, Tellez-Trevilla, Gabriel, Thomas, Randall, Thomssen, Christoph, Toache, Zetina, Tokuda, Yutaka, Tomczak, Piotr, Tosello, Celia, Tsugawa, Koichiro, Tudtud, Dennis, Ueno, Takayuki, Van Eyll, Brigitte, Varela, Mirta, Vasev, Nikola, Vrbanec, Damir, Wang, Xiaojia, Wang, Liwei, Watanabe, Junichiro, Waterhouse, David, Wesenberg, Birgitta, Wheatley, Duncan, Wong, Zee Wan, Yadav, Sanjay, Yardley, Denise, Yau, Tsz-Kok, Yeo, Winnie, Ying, Cheng, Youn Oh, Do, Swain, Sandra M, Miles, David, Kim, Sung-Bae, Im, Young-Hyuck, Im, Seock-Ah, Semiglazov, Vladimir, Ciruelos, Eva, Schneeweiss, Andreas, Loi, Sherene, Monturus, Estefanía, Clark, Emma, Knott, Adam, Restuccia, Eleonora, Benyunes, Mark C, and Cortés, Javier

Published
2020
Full Text
View/download PDF

9. PS2-2 T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04

Author

Tsurutani, Junji, primary, Modi, Shanu, additional, Sohn, Joo Hyuk, additional, Tokunaga, Eriko, additional, Niikura, Naoki, additional, Park, Yeon Hee, additional, Lee, Keun Seok, additional, Chae, Yee Soo, additional, Wang, Xiaojia, additional, Li, Wei, additional, Im, Seock-Ah, additional, Xu, Binghe, additional, Lu, Yen-Shen, additional, Gambhire, Dhiraj, additional, Nishijima, Soichiro, additional, Nishiyama, Yuji, additional, and Sugihara, Masahiro, additional

Published
2023
Full Text
View/download PDF

13. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer

Author

Park, Yeon Hee, Im, Seock-Ah, Kim, Sung-Bae, Sohn, Joo Hyuk, Lee, Keun Seok, Chae, Yee Soo, Lee, Ki Hyeong, Kim, Jee Hyun, Im, Young-Hyuck, Kim, Ji-Yeon, Kim, Tae-Yong, Lee, Kyung-Hun, Ahn, Jin-Hee, Kim, Gun Min, Park, In Hae, Lee, Soo Jung, Han, Hye Sook, Kim, Se Hyun, and Jung, Kyung Hae

Published
2017
Full Text
View/download PDF

15. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Author

Koroveshi, Dhurata, Bouzid, Kamel, Casalnuovo, Monica, Cascallar, Diana, Korbenfeld, Ernesto Pablo, Bastick, Patricia, Beith, Jane, Colosimo, Maree, Friedlander, Michael, Ganju, Vinod, Green, Michael, Patterson, Kevin, Redfern, Andrew, Richardson, Gary, Ceric, Timur, Gordana, Kecman, Beato, Carlos Augusto, Ferrari, Marcela, Hegg, Roberto, Helena, Vanessa, Ismael, Gustavo Fernando, Lessa, Alvaro Edson, Mano, Max, Morelle, Alessandra, Nogueira, Jose Alberto, Timcheva, Konstanta, Tomova, Antoaneta, Tsakova, Maya, Zlatareva-Petrova, Ani, Asselah, Jamil, Assi, Hazem, Brezden-Masley, Christine, Chia, Stephen, Freedman, Ori, Harb, Mohammed, Joy, Anil Abraham, Kulkarni, Swati, Prady, Catherine, Gaete, Alejandro Andres Acevedo, Matamala, Luis, Torres, Roberto, Yanez, Eduardo, Franco, Sandra, Urrego, Marcela, Gugić, Damir, Vrbanec, Damir, Melichar, Bohuslav, Prausová, Jana, Vyzula, Rostislav, Pilarte, Rafael Gutierrez, León, María Isabel, Muñoz, Rene, Ramos, Glenda, Azeem, Hamdy Abdel, Aziz, Amr Abdel, El Zawahry, Heba, Osegueda, Finlander Rosales, Alexandre, Jerome, Artignan, Xavier, Barletta, Hugues, Beguier, Emmanuel, Berdah, Jean-François, Marty, Chantal Bernard, Bollet, Marc, Bourgeois, Hugues, Bressac, Claude, Burki, Franck, Campone, Mario, Coeffic, David, Cojocarasu, Oana Zveltlana, Dagada, Corinne, Dalenc, Florence, Del Piano, Francesco, Desauw, Christophe, Desmoulins, Isabelle, Dohollou, Nadine, Egreteau, Joelle, Ferrero, Jean-Marc, Foa, Cyril, Garidi, Reda, Gasnault, Laurent, Gligorov, Joseph, Guardiola, Emmanuel, Hamizi, Salima, Jarcau, Rosana, Jacquin, Jean-Philippe, Jaubert, Dominique, Jolimoy, Geneviève, Mineur, Hortense Laharie, Largillier, Remy, Leduc, Bernard, Martin, Philippe, Melis, Adrien, Monge, Jeremy, Moullet, Isabelle, Mousseau, Mireille, Nguyen, Suzanne, Orfeuvre, Hubert, Petit, Thierry, Pivot, Xavier, Priou, Frank, Bach, Isabelle Sillet, Simon, Helene, Stefani, Laetitia, Uwer, Lionel, Youssef, Ali, Aktas, Bahriye, von der Assen, Albert, Augustin, Doris, Balser, Christina, Bauer, Lelia-Eveline, Bechtner, Christina, Beyer, Greta, Brucker, Cosima, Bückner, Ute, Busch, Steffi, Christensen, Bernd, Deryal, Mustafa, Farrokh, Andre, Faust, Elke, Friedrichs, Kay, Graf, Heiko, Griesshammer, Martin, Grischke, Eva-Maria, Hänle, Claudia, Heider, Andrea, Henschen, Stephan, Hesse, Tobias, Jackisch, Christian, Kisro, Jens, Köhler, Andreas, Kuemmel, Sherko, Lampe, Dieter, Lantzsch, Tilmann, Latos, Kunibert, Lex, Benno, Liedtke, Cornelia, Luedders, Doerte, Maintz, Christoph, Müller, Volkmar, Overkamp, Friedrich, Park-Simon, Tjoung-won, Paul, Marion, Prechtl, Anita, Ringsdorf, Uta, Runnebaum, Ingo, Ruth, Sylvia, Salat, Christoph, Scheffen, Iris, Schilling, Jörg, Schmatloch, Sabine, Schmidt, Marcus, Schneeweiss, Andreas, Schrader, Iris, Seipelt, Gernot, Simon, Elke, Stefek, Andrea, Stickeler, Elmar, Thill, Marc, Tio, Joke, Tuczek, Anna, Warm, Mathias, Weigel, Michael, Wischnik, Arthur, Wojcinski, Sebastian, Ziegler-Löhr, Katja, Aravantinos, Gerasimos, Ardavanis, Alexandros, Fountzilas, George, Gogas, Helen, Kakolyris, Stylianos, Mavroudis, Dimitris, Papadimitriou, Christos, Papandreou, Christos, Papazisis, Konstantinos, Castro, Hugo, Hernandez-Monroy, Cesar Estuardo, Ngan, Roger, Yeo, Winnie, Bittner, Nora, Boer, Katalin, Csejtei, Andras, Horvath, Zsolt, Kocsis, Judit, Mangel, László Csaba, Mezei, Klara, Nagy, Zsuzsanna, Szanto, Janos, Atmakusuma, Djumhana, Fadjari, Heri, Kurnianda, Djohan, Prayogo, Nugroho, Tanggo, Eddie Herman, Coate, Linda, Hennessy, Bryan, Kelly, Cathy, Martin, Michael, Nasim, Saira, O'Connor, Miriam, Aieta, Michele, Allegrini, Giacomo, Amadori, Dino, Bidoli, Paolo, Biti, Giampaolo, Bordonaro, Roberto, Bottini, Alberto, Carterni, Giacomo, Cavanna, Luigi, Cazzaniga, Marina, Cognetti, Francesco, Contu, Antonio, Cruciani, Giorgio, Donadio, Michela, Falcone, Alfredo, Farci, Daniele, Forcignanò, R. Chiara, Frassoldati, Antonio, Gaion, Fernando, Gamucci, Teresa, Giotta, Francesco, de Laurentiis, Michele, Livi, Lorenzo, Lorusso, Vito, Maiello, Evaristo, Marchetti, Paolo, Mariani, Gabriella, Mion, Marta, Moscetti, Luca, Musolino, Antonino, Pazzola, Antonio, Pedrazzoli, Paolo, Pigi, Andrea, de Placido, Sabino, Caremoli, Elena Rota, Santoro, Armando, Tienghi, Amelia, Ahn, Jin-Seok, Jung, Kyung Hae, Lee, Keun Seok, Lee, Soo Hyeon, Seo, Jae Hong, Sohn, Joo-Hyuk, Cesas, Alvydas, Juozaityte, Elona, Cheah, Nellie Lay Chin, Chong, Flora Li Tze, Devi, Beena C.R., Phua, Vincent, Teoh, Darren, Ching, Lee Wei, Yusof, Mastura, Corona, Jorge, Dominguez, Adriana, Mendoza, René Lazaro González, Hernandez, Carlos Alberto, Ramiro, Alejandro Juarez, Santos, Juan Matos, Espinosa, Paola Morales, Villarreal Garza, Cynthia Mayte, Errihani, Hassan, Bakker, Sandra, van den Berkmortel, Franchette, Blaisse, R.J.B., Huinink, Daan ten Bokkel, van den Bosch, J., Braun, J.J., Dercksen, M.W., Droogendijk, Helga, Erdkamp, Frans, Haringhuizen, Annebeth, de Jongh, F.E., Kok, T.C., Los, Maartje, Madretsma, Stanley, Terwogt, Jetske M. Meerum, van der Padt, Annemieke, van Rossum-Schornagel, Quirine Clementine, Smilde, T.J., de Valk, Bart, van der Velden, Annette, van Warmerdam, Laurence, van de Wouw, A.J., North, Richard, Kersten, Christian, Mjaaland, Ingvild, Wist, Erik, Aziz, Zeba, Masood, Nehal, Rashid, Kamran, Shah, Mazhar, Alcedo, Juan Carlos, Aleman, Diana, Neciosup, Silvia, Reategui, Rocio, Valdiviezo, Natalia, Vera, Luis, Fernando, Gracieux, Roque, Fernando, Strebel, Heinrik Martin, Krzemieniecki, Krzysztof, Litwiniuk, Maria, Mruk, Andrzej, Pienkowski, Tadeusz, Sawrycki, Piotr, Slomian, Grzegorz, Tomczak, Piotr, Afonso, Noemia, Cardoso, Fátima, Damasceno, Margarida, Nave, Monica, Badulescu, Florinel, Ciule, Larisa, Curescu, Stefan, Eniu, Alexandru, Filip, Dumitru, Grecea, Daniela, Jinga, Dan-Corneliu, Lungulescu, Dan, Oprean, Cristina Marinela, Stanculeanu, Dana Lucia, Turdean, Maria, Dvornichenko, Viktoria, Emelyanov, Sergey, Lichinitser, Mikhail, Manikhas, Alexey, Sakaeva, Dina, Shirinkin, Vadim, Stroyakovskiy, Daniil, Abulkhair, Omalkhair, Zekri, Jamal, Filipovic, Sladjana, Kovcin, Vladimir, Nedovic, Jasmina, Pesic, Jasna, Vasovic, Suzana, Ng, Raymond, Bystricky, Branislav, Leskova, Jaroslava, Mardiak, Jozef, Mišurová, Etela, Wagnerova, Maria, Takač, Iztok, Demetriou, Georgia Savva, Dreosti, Lydia, Govender, Poovandren, Jordaan, Johannes Petrus, Veersamy, Petrosian, Romero, Jose Luis Alonso, Lopez, Norberto Batista, Arias, Carmen Cañabate, Chacon, Jose, Aramburo, Antonio Fernandez, Morales, Luis Antonio Fernandez, Garcia, Mirta, Estevez, Laura Garcia, Garcia-Palomo Perez, Andres, Garcia Saenz, Jose Angel, Garcia Sanchis, Laura, Cubells, Laia Garrigos, Cortijo, Lucia Gonzalez, Santiago, Santiago Gonzalez, De Aranguiz, Blanca Hernando Fernandez, Mañas, José Juan Illarramendi, Gallego, Pedro Jimenez, Cussac, Antonio Llombart, Ferrandiz, Cristina Llorca, Garrido, Maria Lomas, Alvarez, Pilar Lopez, Vega, Jose Manuel Lopez, Del Prado, Purificacion Martinez, Jañez, Noelia Martinez, Murillo, Serafin Morales, Rosales, Adolfo Murias, Jaso, Laura Murillo, Fernandez, Ignacio Pelaez, Martorell, Antonia Perello, Carrion, Ramon Perez, Simon, Sonia Pernas, Alcibar, Arrate Plazaola, Lorenzo, Jose Ponce, Garcia, Vanesa Quiroga, Asensio, Teresa Ramon y Cajal, Maicas, Maria Dolores Torregrosa, Villanueva Silva, Maria Jose, Killander, Fredrika, Svensson, Jan Henry, Fehr, Mathias, Hauser, Nik, Müller, Andreas, Pagani, Olivia, Passmann-Kegel, Heike, Popescu, Razvan, Rabaglio, Manuela, Rauch, Daniel, Schlatter, Christina, Zaman, Khalil, Chang, Tsai-Wang, Huang, Chiun-Sheng, Wang, Hwei-Chung, Yu, Jyh-Cherng, Bandidwattanawong, Chanyoot, Maneechavakajorn, Jedzada, Seetalarom, Kasan, Dejthevaporn, Thitiya (Sirisinha), Somwangprasert, Areewan, Vongsaisuwon, Mawin, Akbulut, Hakan, Altundag, Kadri, Arican, Ali, Bozcuk, Hakan, Eralp, Yesim, Idris, Mohamed, Isikdogan, Abdurrahman, Senol, Coskun Hasan, Sevinc, Alper, Uygun, Kazim, Yucel, Eftal, Yucel, Idris, Yumuk, Fulden, Shparyk, Yaroslav, Voitko, Nataliia, Jaloudi, Mohammed, Adams, Jocelyn, Agrawal, Rajiv, Ahmed, Samreen, Alhasso, Abdulla, Allerton, Rozenn, Anwar, Suhail, Archer, Caroline, Ashford, Richard, Barraclough, Lisa, Bertelli, Gianfilippo, Bishop, Jill, Branson, Tony, Butt, Mohammed, Chakrabarti, Amit, Chakraborti, Prabir, Churn, Mark, Crowley, Clare, Davis, Ruth, Dhadda, Amandeep, Eldeeb, Hany, Fraser, Judith, Hall, Julia, Hickish, Tamas, Hogg, Martin, Howe, Theresa, Joffe, Jonathan, Kelleher, Muireann, Kelly, Stephen, Kendall, Anne, Kristeleit, Hartmut, Lumsden, Graeme, Macmillan, Craig, MacPherson, Iain, Malik, Zafar, Mithal, Natasha, Neal, Anthony, Panwar, Udaiveer, Proctor, Andrew, Proctor, Steven John, Raj, Sanjay, Rehman, Shazza, Sandri, Ines, Scatchard, Kate, Sherwin, Elizabeth, Sims, Eliot, Singer, Julian, Smith, Sarah, Tahir, Saad, Taylor, Wendy, Tsalic, Medy, Verrill, Mark, Wardley, Andrew, Waters, Simon, Wheatley, Duncan, Wright, Kathryn, Yuille, Frances, Alonso, Isabel, Artagaveytia, Nora, Rodriguez, Robinson, Arbona, Esther, Garcia, Yuraima, Lion, Lorena, Marcano, Dalila, Van Thuan, Tran, Gligorov, J., Ataseven, B., Verrill, M., De Laurentiis, M., Jung, K.H., Azim, H.A., Al-Sakaff, N., Lauer, S., Shing, M., and Pivot, X.

Published
2017
Full Text
View/download PDF

18. Abstract P5-03-14: Prevalence of germline BRCA mutations in unselected Korean patients with HER2-negative breast cancer: A Prospective cohort study

Author

Ahn, Hee Kyung, primary, Kim, Jee Hung, additional, Kim, Mirae, additional, Park, Seri, additional, Koh, Su-Jin, additional, Sohn, Joo Hyuk, additional, Kang, Myoung Joo, additional, Jung, Kyung Hae, additional, Lee, Kyoung Eun, additional, Lee, Jieun, additional, Koh, Sung Ae, additional, Chae, Yee Soo, additional, Byun, Jae Ho, additional, Park, In Hae, additional, Kim, Hee-Jun, additional, Kim, Jee Hyun, additional, Kim, Han Jo, additional, Jung, Joo Young, additional, Lee, Jung Lim, additional, Cho, Yoon Young, additional, Park, Kyong Hwa, additional, Kim, Ji-Yeon, additional, Im, Seock-Ah, additional, and Park, Yeon Hee, additional

Published
2023
Full Text
View/download PDF

19. Abstract PD18-09: ACE-Breast-03: Efficacy and safety of ARX788 in patients with HER2+ metastatic breast cancer previously treated with T-DM1

Author

Hurvitz, Sara, primary, Kalinsky, Kevin, additional, Ganju, Vinod, additional, Ali, Kashif, additional, Agrawal, Laila, additional, Gradishar, William, additional, Sledge, George, additional, Thummala, Anu, additional, Chan, Arlene, additional, Frentzas, Sophia, additional, Sohn, Joo Hyuk, additional, Park, Kyong-Hwa, additional, Park, Keon Uk, additional, Shannon, Catherine, additional, Drago, Joshua, additional, Tolaney, Sara, additional, Rugo, Hope, additional, Press, Michael F., additional, Alika, Alex, additional, Xu, Dong, additional, Lu, Janice, additional, and Tripathy, Debu, additional

Published
2023
Full Text
View/download PDF

20. Abstract P1-11-01: Trastuzumab deruxtecan vs treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup analyses from DESTINY-Breast04

Author

Harbeck, Nadia, primary, Modi, Shanu, additional, Jacot, William, additional, Yamashita, Toshinari, additional, Sohn, Joo Hyuk, additional, Vidal, Maria, additional, Tsurutani, Junji, additional, Ueno, Naoto T., additional, Prat, Aleix, additional, Niikura, Naoki, additional, Xu, Binghe, additional, Rugo, Hope, additional, Papazisis, Konstantinos, additional, Cortés, Javier, additional, Krop, Ian, additional, Gambhire, Dhiraj, additional, Yung, Lotus, additional, Wang, Yibin, additional, Singh, Jasmeet, additional, and Cameron, David, additional

Published
2023
Full Text
View/download PDF

21. Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting

Author

Bardia, Aditya, primary, Bidard, Francois-Clement, additional, Neven, Patrick, additional, Streich, Guillermo, additional, Montero, Alberto J., additional, Forget, Frederic, additional, Mouret-Reynier, Marie-Ange, additional, Sohn, Joo Hyuk, additional, Taylor, Donatienne, additional, Harnden, Kathleen K., additional, Khong, Hung, additional, Kocsis, Judit, additional, Dalenc, Florence, additional, Dillon, Patrick, additional, Babu, Sunil, additional, Waters, Simon, additional, Deleu, Ines, additional, García-Sáenz, Jose Angel, additional, Bria, Emilio, additional, Cazzaniga, Marina Elena, additional, Aftimos, Philippe, additional, Cortés, Javier, additional, Tonini, Giulia, additional, Sahmoud, Tarek, additional, Habboubi, Nassir, additional, Grzegorzewski, Krzysztof, additional, and Kaklamani, Virginia, additional

Published
2023
Full Text
View/download PDF

22. Abstract OT2-16-03: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

Author

Hamilton, Erika, primary, Tsurutani, Junji, additional, Curigliano, Giuseppe, additional, Martín, Miguel, additional, O’Sullivan, Ciara C., additional, Sohn, Joo Hyuk, additional, Tryfonidis, Konstantinos, additional, Santarpia, Libero, additional, Yang, Shan, additional, and Diéras, Véronique, additional

Published
2023
Full Text
View/download PDF

23. Abstract OT1-03-04: Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy in previously-treated, inoperable or metastatic HR+/HER2– breast cancer: TROPION-Breast01

Author

Bardia, Aditya, primary, Kalinsky, Kevin, additional, Tsurutani, Junji, additional, Hamilton, Erika, additional, Sohn, Joo Hyuk, additional, Park, Kyong Hwa, additional, Park, Yeon Hee, additional, Im, Seock-Ah, additional, Lee, Keun Seok, additional, Dastur, Daisy, additional, Haddad, Vincent, additional, Khan, Sabrina, additional, Xu, Binghe, additional, Pistilli, Barbara, additional, and Rugo, Hope, additional

Published
2023
Full Text
View/download PDF

24. Abstract PD13-04: PD13-04 Exploratory subgroup and biomarker analyses of acelERA Breast Cancer: Phase II study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy for previously treated, estrogen receptor+, HER2– advanced breast cancer

Author

Lim, Elgene, primary, Chavez, Marianna, additional, Bardia, Aditya, additional, Sohn, Joo Hyuk, additional, Moore, Heather M., additional, Shivhare, Mahesh, additional, Martinalbo, Jorge, additional, Roncoroni, Laura, additional, Perez-Moreno, Pablo D., additional, and Martín, Miguel, additional

Published
2023
Full Text
View/download PDF

25. Abstract PD13-11: PD13-11 Final Overall Survival Analysis of Monarch 2 : A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Author

Llombart-Cussac, Antonio, primary, Sledge, George, additional, Toi, Masakazu, additional, Neven, Patrick, additional, Sohn, Joo Hyuk, additional, Inoue, Kenichi, additional, Pivot, Xavier, additional, Okera, Meena, additional, Masuda, Norikazu, additional, Kaufman, Peter A., additional, Koh, Han, additional, Grischke, Eva-Maria, additional, Conte, PierFranco, additional, Andre, Valerie, additional, Bian, Yuanyuan, additional, Shahir, Ashwin, additional, and van Hal, Gertjan, additional

Published
2023
Full Text
View/download PDF

26. Abstract P5-02-32: Differential Gene Mutation Landscape in Patients With PIK3CA-altered and Non-altered Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer in the SOLAR-1 Clinical Study

Author

Juric, Dejan, primary, Rugo, Hope, additional, Reising, Albert, additional, Ma, Chong, additional, Ciruelos, Eva, additional, Loibl, Sibylle, additional, Singer, Christian F., additional, Sohn, Joo Hyuk, additional, Campone, Mario, additional, Conte, PierFranco, additional, Iwata, Hiroji, additional, Ghaznawi, Farhat, additional, Miller, Michelle, additional, Taran, Tetiana, additional, Su, Faye, additional, and Andre, Fabrice, additional

Published
2023
Full Text
View/download PDF

27. Abstract P5-14-04: Genomic characterization of hormone receptor-positive advanced breast cancer with high tumor mutational burden: fresh-frozen tissue genomic analysis from MUTATION-1 study (KCSG BR17-04)

Author

Kim, Min Hwan, primary, Yang, Yohan, additional, Kim, Eunyoung, additional, Moon, Yong Wha, additional, Kim, Gun Min, additional, Kim, Seul-Gi, additional, Chae, Yee Soo, additional, Lee, Jieun, additional, Jeong, Jae Ho, additional, Lee, Kyung-Hun, additional, Kim, Han Jo, additional, Jung, Joo Young, additional, Koh, Su-Jin, additional, Lee, Kyoung Eun, additional, Kim, Hee-Jun, additional, Park, Kyong Hwa, additional, Lim, Seungtaek, additional, Park, Yeon Hee, additional, Kim, Sangwoo, additional, and Sohn, Joo Hyuk, additional

Published
2023
Full Text
View/download PDF

28. Abstract HER2-15: HER2-15 Retrospective Study to Estimate the Prevalence and Describe the Clinicopathological Characteristics, Treatment Patterns, and Outcomes of HER2-Low Breast Cancer

Author

Viale, Giuseppe, primary, Basik, Mark, additional, Niikura, Naoki, additional, Tokunaga, Eriko, additional, Brucker, Sara, additional, Penault-Llorca, Frédérique, additional, Hayashi, Naoki, additional, Sohn, Joo Hyuk, additional, de Sousa, Rita Teixeira, additional, Brufsky, Adam M., additional, O’Brien, Ciara S., additional, Schmitt, Fernando, additional, Higgins, Gavin, additional, Varghese, Della, additional, James, Gareth D., additional, Moh, Akira, additional, Livingston, Andrew, additional, and de Giorgio-Miller, Victoria, additional

Published
2023
Full Text
View/download PDF

29. Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea

Author

Lee, Si Won, primary, Kwon, Jung Hye, additional, Beom, Seung-hoon, additional, Shin, Sang Joon, additional, Kim, Hyo Song, additional, Rha, Sun Young, additional, Jung, Minkyu, additional, Sohn, Joo Hyuk, additional, Ahn, Joong-Bae, additional, Chung, Hyun Cheol, additional, Kim, Gun Min, additional, Kim, Hye Ryun, additional, Kang, Beodeul, additional, Hu, Youn Jung, additional, and Choi, Hye Jin, additional

Published
2023
Full Text
View/download PDF

30. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

Author

Cortés, Javier, Dieras, Véronique, Ro, Jungsil, Barriere, Jérôme, Bachelot, Thomas, Hurvitz, Sara, Le Rhun, Emilie, Espié, Marc, Kim, Sung-Bae, Schneeweiss, Andreas, Sohn, Joo Hyuk, Nabholtz, Jean-Marc, Kellokumpu-Lehtinen, Pirkko-Liisa, Taguchi, Julie, Piacentini, Federico, Ciruelos, Eva, Bono, Petri, Ould-Kaci, Mahmoud, Roux, Flavien, and Joensuu, Heikki

Published
2015
Full Text
View/download PDF

32. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Author

Bidard, Francois-Clement, primary, Kaklamani, Virginia G., additional, Neven, Patrick, additional, Streich, Guillermo, additional, Montero, Alberto J., additional, Forget, Frédéric, additional, Mouret-Reynier, Marie-Ange, additional, Sohn, Joo Hyuk, additional, Taylor, Donatienne, additional, Harnden, Kathleen K., additional, Khong, Hung, additional, Kocsis, Judit, additional, Dalenc, Florence, additional, Dillon, Patrick M., additional, Babu, Sunil, additional, Waters, Simon, additional, Deleu, Ines, additional, García Sáenz, José A., additional, Bria, Emilio, additional, Cazzaniga, Marina, additional, Lu, Janice, additional, Aftimos, Philippe, additional, Cortés, Javier, additional, Liu, Shubin, additional, Tonini, Giulia, additional, Laurent, Dirk, additional, Habboubi, Nassir, additional, Conlan, Maureen G., additional, and Bardia, Aditya, additional

Published
2022
Full Text
View/download PDF

34. Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer

Author

Ahn, Hee Kyung, primary, Sim, Sung Hoon, additional, Suh, Koung Jin, additional, Kim, Min Hwan, additional, Jeong, Jae Ho, additional, Kim, Ji-Yeon, additional, Lee, Dae-Won, additional, Ahn, Jin-Hee, additional, Chae, Heejung, additional, Lee, Kyung-Hun, additional, Kim, Jee Hyun, additional, Lee, Keun Seok, additional, Sohn, Joo Hyuk, additional, Choi, Yoon-La, additional, Im, Seock-Ah, additional, Jung, Kyung Hae, additional, and Park, Yeon Hee, additional

Published
2022
Full Text
View/download PDF

35. Abstract 6371: Deep learning algorithm for multi-cancer detection and classification using cf-WGS

Author

Lee, Tae-Rim, primary, Ahn, Jin Mo, additional, Sohn, Joo Hyuk, additional, Park, Sook Ryun, additional, Kim, Min Hwan, additional, Kim, Gun Min, additional, Song, Ki-Byung, additional, Jun, Eunsung, additional, Oh, Dongryul, additional, Lee, Jeong-Won, additional, Noh, Joseph J, additional, Park, Young Sik, additional, Kong, Sun-Young, additional, Woo, Sang Myung, additional, Kim, Bo Hyun, additional, Chie, Eui Kyu, additional, Kang, Hyun-Cheol, additional, Choi, Youn Jin, additional, Song, Ki-Won, additional, Byeon, Jeong-Sik, additional, Lee, Junnam, additional, Kim, Dasom, additional, Ki, Chang-Seok, additional, and Cho, Eunhae, additional

Published
2022
Full Text
View/download PDF

36. Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)

Author

Park, Yeon Hee, Jung, Kyung Hae, Im, Seock-Ah, Sohn, Joo Hyuk, Ro, Jungsil, Ahn, Jin-Hee, Kim, Sung-Bae, Nam, Byung-Ho, Oh, Do Youn, Han, Sae-Won, Lee, Soohyeon, Park, In Hae, Lee, Keun Seok, Kim, Jee Hyun, Kang, Seok Yun, Lee, Moon Hee, Park, Hee Sook, Woo, Sook Young, Jung, Sin-Ho, Ahn, Jin Seok, Im, Young-Hyuck, and Korean Cancer Study Group (KCSG)

Published
2015
Full Text
View/download PDF

37. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Author

Baselga, José, Bradbury, Ian, Eidtmann, Holger, Di Cosimo, Serena, de Azambuja, Evandro, Aura, Claudia, Gómez, Henry, Dinh, Phuong, Fauria, Karine, Van Dooren, Veerle, Aktan, Gursel, Goldhirsch, Aron, Chang, Tsai-Wang, Horváth, Zsolt, Coccia-Portugal, Maria, Domont, Julien, Tseng, Ling-Min, Kunz, Georg, Sohn, Joo Hyuk, Semiglazov, Vladimir, Lerzo, Guillermo, Palacova, Marketa, Probachai, Volodymyr, Pusztai, Lajos, Untch, Michael, Gelber, Richard D, and Piccart-Gebhart, Martine

Published
2012
Full Text
View/download PDF

38. Abstract GS2-02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial

Author

Bardia, Aditya, primary, Neven, Patrick, additional, Streich, Guillermo, additional, Montero, Alberto J., additional, Forget, Frédéric, additional, Mouret-Reynier, Marie-Ange, additional, Sohn, Joo Hyuk, additional, Vuylsteke, Peter, additional, Harnden, Kathleen K., additional, Khong, Hung, additional, Kocsis, Judit, additional, Dalenc, Florence, additional, Kaklamani, Virginia, additional, Dillon, Patrick, additional, Babu, Sunil, additional, Waters, Simon, additional, Deleu, Ines, additional, García-Sáenz, José, additional, Bria, Emilio, additional, Cazzaniga, Marina, additional, Lu, Janice, additional, Aftimos, Philippe, additional, Cortes, Javier, additional, Liu, Shubin, additional, Laurent, Dirk, additional, Conlan, Maureen G., additional, and Bidard, Francois-Clement, additional

Published
2022
Full Text
View/download PDF

42. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

Author

Gelmon, Karen A., primary, Fasching, Peter A., additional, Couch, Fergus J., additional, Balmaña, Judith, additional, Delaloge, Suzette, additional, Labidi-Galy, Intidhar, additional, Bennett, James, additional, McCutcheon, Susan, additional, Walker, Graham, additional, O'Shaughnessy, Joyce, additional, Timcheva, Constanta, additional, Tomova, Antoaneta, additional, Eisen, Andrea, additional, Gelmon, Karen, additional, Lemieux, Julie, additional, Bazan, Fernando, additional, Bourgeois, Hugues, additional, Chakiba, Camille, additional, Chehimi, Mohamad, additional, Dalenc, Florence, additional, De La Motte Rouge, Thibault, additional, Frenel, Jean-Sébastien, additional, Gonçalves, Anthony, additional, Hardy-Bessard, Anne Claire, additional, Lamy, Regine, additional, Levy, Christelle, additional, Lortholary, Alain, additional, Mailliez, Audrey, additional, Medioni, Jacques, additional, Patsouris, Anne, additional, Spaeth, Dominique, additional, Teixeira, Luis, additional, Tennevet, Isabelle, additional, Villanueva, Cristian, additional, You, Benoit, additional, Ettl, Johannes, additional, Gerber, Bernd, additional, Hoffmann, Oliver, additional, Park-Simon, Tjoung-Won, additional, Reinisch, Mattea, additional, Tio, Joke, additional, Wimberger, Pauline, additional, Boer, Katalin, additional, Ballestrero, Alberto, additional, Bianchini, Giampaolo, additional, Biganzoli, Laura, additional, Bordonaro, Roberto, additional, Cognetti, Francesco, additional, De Laurentiis, Michelino, additional, De Placido, Sabino, additional, Guarneri, Valentina, additional, Montemurro, Filippo, additional, Naso, Giuseppe, additional, Santoro, Armando, additional, Zamagni, Claudio, additional, Kim, Seung-Jin, additional, Nakamura, Seigo, additional, Chae, Yee Soo, additional, Cho, Eun Kyung, additional, Hyun, Kim Jee, additional, Im, Seock-Ah, additional, Lee, Keun Seok, additional, Park, Yeon Hee, additional, Sohn, Joo Hyuk, additional, Byrski, Tomasz, additional, Huzarski, Tomasz, additional, Kukielka-Budny, Bozena, additional, Nowecki, Zbigniew, additional, Szoszkiewicz, Renata, additional, Tarnawski, Rafal, additional, Dvornichenko, Viktoria, additional, Moiseenko, Fedor, additional, Mukhametshina, Guzel, additional, Poddubskaya, Elena, additional, Popova, Ekaterina, additional, Tarasova, Anna, additional, Vats, Anna, additional, Adamo, Bárbara, additional, Conejero, Raquel Andrés, additional, Torres, Antonio Antón, additional, Gelpi, Judith Balmaña, additional, Fernández, Nieves Díaz, additional, González, Alejandro Falcón, additional, Garcia, Juan, additional, Lorenzo-Lorenzo, Isabel, additional, Antón, Fernando Moreno, additional, Santisteban, Marta, additional, Stradella, Agostina, additional, Huang, Chiun-Sheng, additional, Aksoy, Sercan, additional, Arslan, Cagatay, additional, Artac, Mehmet, additional, Aydiner, Adnan, additional, Ozyilkan, Ozgur, additional, Sezer, Emel, additional, Armstrong, Anne, additional, Barrett, Sophie, additional, Borley, Annabel, additional, Kemp, Zoe, additional, Michie, Caroline, additional, Mukesh, Mukesh, additional, Perren, Timothy, additional, Swampillai, Angela, additional, and Young, Tammy, additional

Published
2021
Full Text
View/download PDF

43. Abstract CT234: VASTUS - a phase 1b/2a basket trial of a new PARP inhibitor, IDX-1197, including PARP inhibitor resistant cohort

Author

Lee, Kyung-Hun, primary, Min, Ahrum, additional, Ahn, Hee Kyung, additional, Lee, Keun Seok, additional, Moon, Yong Wha, additional, Kim, Seung Tae, additional, Kim, Jeong Eun, additional, Sohn, Joo Hyuk, additional, Kim, Il Hwan, additional, Bae, Woo Kyun, additional, Lee, Myong Jae, additional, Roh, Eun-Jihn, additional, Ock, Chan-Young, additional, Lee, Won Sik, additional, and Im, Seock-Ah, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results